St. Jude Medical (STJ) 77.52 $STJ
India Cardiovascular Devices Market Report 2016-2021 - Analysis, Technologies & Forecasts - Key Vendors: Medtronic, St. Jude Medical, Abbott Labs - Research and Markets
BusinessWire - Fri Jun 10, 12:10PM CDT
Research and Markets has announced the addition of the "India Cardiovascular Devices Market Outlook to 2021 - Cardiac Rhythm Management, Interventional Cardiology, Peripheral Vascular Devices, Electrophysiology, Prosthetic Heart Valves and Others" report to their offering.
ABT: 38.36 (-0.04), MDT: 86.15 (+0.45), STJ: 77.52 (+0.17)
43.9% Return Seen to Date on SmarTrend St Jude Medical Call (STJ)
Comtex SmarTrend(R) - Thu Jun 09, 12:23AM CDT
SmarTrend identified an Uptrend for St Jude Medical (NYSE:STJ) on February 22nd, 2016 at $54.18. In approximately 4 months, St Jude Medical has returned 43.89% as of today's recent price of $77.96.
STJ: 77.52 (+0.17)
Technical Pulse on Medical Appliances & Equipment Stocks -- St. Jude Medical, ResMed, Steris, and Varian Medical Systems
PR Newswire - Mon Jun 06, 8:00AM CDT
On Friday, June 03, 2016, the NASDAQ Composite ended the trading session at 4,942.52, down 0.58%; the Dow Jones Industrial Average lost 0.18% to finish at 17,807.06; and the S&P 500 closed at 2,099.13, down 0.29%. ActiveWallSt.com has initiated coverage on the following equities: St. Jude Medical Inc. (NYSE: STJ), ResMed Inc. (NYSE: RMD), Steris PLC (NYSE: STE), and Varian Medical Systems Inc. (NYSE: VAR). Learn more about these stocks by accessing their free trade alerts at:
VAR: 84.85 (-0.45), STE: 69.31 (-1.43), RMD: 59.70 (-0.10), STJ: 77.52 (+0.17), MDSY: 1.50 (-0.04)
St. Jude Medical CardioMEMS HF System is Now Guideline Directed Therapy for Heart Failure Patients in Europe
BusinessWire - Mon Jun 06, 7:00AM CDT
St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced that its CardioMEMS(TM) HF System was added to the European Society of Cardiology (ESC) guidelines as a directed therapy management and monitoring tool for heart failure patients. The new 2016 ESC Clinical Practice Guidelines for the diagnosis and treatment of acute and chronic heart failure for the first time include pulmonary artery pressure monitoring with the CardioMEMS HF System.
STJ: 77.52 (+0.17)
Uptrend Call Working As St Jude Medical Stock Rises 44.5% (STJ)
Comtex SmarTrend(R) - Wed Jun 01, 12:48PM CDT
SmarTrend identified an Uptrend for St Jude Medical (NYSE:STJ) on February 22nd, 2016 at $54.18. In approximately 3 months, St Jude Medical has returned 44.54% as of today's recent price of $78.31.
STJ: 77.52 (+0.17)
BRIC Interventional Cardiology Market Report 2016-2021 - Analysis, Technologies & Forecasts - Key Vendors: Abbott Labs, Medtronic, St. Jude Medical - Research and Markets
BusinessWire - Fri May 27, 6:25AM CDT
Research and Markets has announced the addition of the "BRIC Interventional Cardiology Market Outlook to 2021" report to their offering.
ABT: 38.36 (-0.04), MDT: 86.15 (+0.45), STJ: 77.52 (+0.17)
California Life Sciences Association Elects Leaders from Merck, Organovo and St. Jude Medical to its Board of Directors
Marketwire Canada - Tue May 24, 11:30AM CDT
SAN FRANCISCO, CA and SAN DIEGO, CA--(Marketwired - May 24, 2016) - Today, California Life Sciences Association (CLSA) announced its board of directors has appointed three new members: Ben Thorner, Vice President, BD&L and Head of North American Innovation Hubs, Merck; Keith Murphy, Chairman and Chief Executive Officer, Organovo; and Dave Anderson, Vice President, Merger & Acquisition Integration, St. Jude Medical.
MRK: 56.59 (-0.22), STJ: 77.52 (+0.17)
New Data Presented at EuroPCR 2016 Adds to the Growing Body of Clinical Evidence Supporting St. Jude Medical FFR Technology and LAA Closure
BusinessWire - Thu May 19, 3:47AM CDT
St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced results from two cardiovascular clinical trials presented at EuroPCR 2016. The studies, which include a look at how St. Jude Medical(TM) fractional flow reserve (FFR) technology impacts patient outcomes in Acute Coronary Syndrome (ACS) and a comparison of left atrial appendage occlusion (LAAO) therapy to standard medical treatment - were presented during hotline sessions.
STJ: 77.52 (+0.17)
St. Jude Medical Announces European Launch of the Latest in PressureWire Guidewire Technology to Measure Pressure Differences Across Narrowed Coronary Arteries
BusinessWire - Wed May 18, 7:00AM CDT
St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced CE Mark approval and European launch of the PressureWire(TM) X Guidewire fractional flow reserve (FFR) Measurement System. Designed to identify the severity of narrowings in the coronary arteries of patients with coronary artery disease (CAD), FFR measurement allows for a more effective assessment of coronary lesions (blockages), resulting in more accurate diagnosis. The company will showcase the new PressureWire X guidewire technology at the EuroPCR 2016 meeting, May 17-20, 2016 in Paris. The PressureWire X guidewire European launch will include a measured rollout to targeted countries throughout 2016.
STJ: 77.52 (+0.17)
BRIC Prosthetic Heart Valves Market Outlook to 2021 - Key Players are Edwards Lifesciences, Medtronic & St. Jude Medical, Inc - Research and Markets
BusinessWire - Tue May 17, 4:16AM CDT
Research and Markets has announced the addition of the "BRIC Prosthetic Heart Valves Market Outlook to 2021" report to their offering.
STJ: 77.52 (+0.17)
Asia-Pacific Prosthetic Heart Valves Market Outlook to 2021 - Key Players are Edwards Lifesciences Corporation, Medtronic plc, St. Jude Medical - Research and Markets
BusinessWire - Mon May 16, 8:00AM CDT
Research and Markets has announced the addition of the "Asia-Pacific Prosthetic Heart Valves Market Outlook to 2021" report to their offering.
MDT: 86.15 (+0.45), STJ: 77.52 (+0.17)
France Cardiovascular Devices Market Outlook to 2021 Featuring Key Players, Medtronic, Boston Scientific, St. Jude Medical, Inc & Abbott Laboratories - Research and Markets
BusinessWire - Mon May 16, 7:49AM CDT
Research and Markets has announced the addition of the "France Cardiovascular Devices Market Outlook to 2021" report to their offering.
BSX: 23.04 (+0.02), ABT: 38.36 (-0.04), MDT: 86.15 (+0.45), STJ: 77.52 (+0.17)
St. Jude Medical Furthers the Company's Legacy of Heart Valve Excellence With US Launch of the Trifecta Surgical Valve With Glide Technology
BusinessWire - Mon May 16, 7:00AM CDT
St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced the U.S. launch of the company's most advanced tissue valve -- the Trifecta(TM) valve with Glide(TM) Technology (GT) -- for the treatment of patients diagnosed with unhealthy, damaged or malfunctioning aortic heart valves. Designed with feedback from a cohort of international physicians, the Trifecta GT tissue valve offers patients the benefit of enhanced valve delivery to ease implantation in challenging anatomies and during minimally invasive surgical approaches.
STJ: 77.52 (+0.17)
St. Jude Medical (STJ) Shares March Higher, Can It Continue?
Zacks Equity Research - Zacks Investment Research - Thu May 12, 8:52AM CDT
As of late, it has definitely been a great time to be an investor in St. Jude Medical Inc. (STJ)
STJ: 77.52 (+0.17)
Downgrade Alert for St Jude Medical (STJ)
Comtex SmarTrend(R) - Thu May 12, 3:08AM CDT
St Jude Medical (NYSE:STJ) was downgraded from Overweight to Equal Weight at Barclays Capital today. The stock closed yesterday at $75.68 on volume of 4.6 million shares, above average daily volume of 4.3 million. Based on a current price of $75.68, St Jude Medical is currently 2.4% above its average consensus analyst price target of $73.85. The stock should discover initial support at its 200-day moving average (MA) of $62.17 and subsequent support at its 50-day MA of $58.64.
STJ: 77.52 (+0.17)
EU5 Cardiovascular Prosthetic Devices Market Report 2016-2021 - Analysis, Technologies & Forecasts - Key Vendors: Medtronic, St. Jude Medical, Sorin - Research and Markets
BusinessWire - Tue May 10, 11:14AM CDT
Research and Markets has announced the addition of the "EU5 Cardiovascular Prosthetic Devices Market Outlook to 2021" report to their offering.
MDT: 86.15 (+0.45), STJ: 77.52 (+0.17)
India Cardiovascular Devices Market Report 2016-2021 - Analysis, Technologies & Forecasts - Key Vendors: Medtronic, St. Jude Medical, Abbott Labs - Research and Markets
BusinessWire - Fri Jun 10, 12:10PM CDT
Research and Markets has announced the addition of the "India Cardiovascular Devices Market Outlook to 2021 - Cardiac Rhythm Management, Interventional Cardiology, Peripheral Vascular Devices, Electrophysiology, Prosthetic Heart Valves and Others" report to their offering.
ABT: 38.36 (-0.04), MDT: 86.15 (+0.45), STJ: 77.52 (+0.17)
43.9% Return Seen to Date on SmarTrend St Jude Medical Call (STJ)
Comtex SmarTrend(R) - Thu Jun 09, 12:23AM CDT
SmarTrend identified an Uptrend for St Jude Medical (NYSE:STJ) on February 22nd, 2016 at $54.18. In approximately 4 months, St Jude Medical has returned 43.89% as of today's recent price of $77.96.
STJ: 77.52 (+0.17)
Technical Pulse on Medical Appliances & Equipment Stocks -- St. Jude Medical, ResMed, Steris, and Varian Medical Systems
PR Newswire - Mon Jun 06, 8:00AM CDT
On Friday, June 03, 2016, the NASDAQ Composite ended the trading session at 4,942.52, down 0.58%; the Dow Jones Industrial Average lost 0.18% to finish at 17,807.06; and the S&P 500 closed at 2,099.13, down 0.29%. ActiveWallSt.com has initiated coverage on the following equities: St. Jude Medical Inc. (NYSE: STJ), ResMed Inc. (NYSE: RMD), Steris PLC (NYSE: STE), and Varian Medical Systems Inc. (NYSE: VAR). Learn more about these stocks by accessing their free trade alerts at:
VAR: 84.85 (-0.45), STE: 69.31 (-1.43), RMD: 59.70 (-0.10), STJ: 77.52 (+0.17), MDSY: 1.50 (-0.04)
St. Jude Medical CardioMEMS HF System is Now Guideline Directed Therapy for Heart Failure Patients in Europe
BusinessWire - Mon Jun 06, 7:00AM CDT
St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced that its CardioMEMS(TM) HF System was added to the European Society of Cardiology (ESC) guidelines as a directed therapy management and monitoring tool for heart failure patients. The new 2016 ESC Clinical Practice Guidelines for the diagnosis and treatment of acute and chronic heart failure for the first time include pulmonary artery pressure monitoring with the CardioMEMS HF System.
STJ: 77.52 (+0.17)
Uptrend Call Working As St Jude Medical Stock Rises 44.5% (STJ)
Comtex SmarTrend(R) - Wed Jun 01, 12:48PM CDT
SmarTrend identified an Uptrend for St Jude Medical (NYSE:STJ) on February 22nd, 2016 at $54.18. In approximately 3 months, St Jude Medical has returned 44.54% as of today's recent price of $78.31.
STJ: 77.52 (+0.17)
BRIC Interventional Cardiology Market Report 2016-2021 - Analysis, Technologies & Forecasts - Key Vendors: Abbott Labs, Medtronic, St. Jude Medical - Research and Markets
BusinessWire - Fri May 27, 6:25AM CDT
Research and Markets has announced the addition of the "BRIC Interventional Cardiology Market Outlook to 2021" report to their offering.
ABT: 38.36 (-0.04), MDT: 86.15 (+0.45), STJ: 77.52 (+0.17)
California Life Sciences Association Elects Leaders from Merck, Organovo and St. Jude Medical to its Board of Directors
Marketwire Canada - Tue May 24, 11:30AM CDT
SAN FRANCISCO, CA and SAN DIEGO, CA--(Marketwired - May 24, 2016) - Today, California Life Sciences Association (CLSA) announced its board of directors has appointed three new members: Ben Thorner, Vice President, BD&L and Head of North American Innovation Hubs, Merck; Keith Murphy, Chairman and Chief Executive Officer, Organovo; and Dave Anderson, Vice President, Merger & Acquisition Integration, St. Jude Medical.
MRK: 56.59 (-0.22), STJ: 77.52 (+0.17)
New Data Presented at EuroPCR 2016 Adds to the Growing Body of Clinical Evidence Supporting St. Jude Medical FFR Technology and LAA Closure
BusinessWire - Thu May 19, 3:47AM CDT
St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced results from two cardiovascular clinical trials presented at EuroPCR 2016. The studies, which include a look at how St. Jude Medical(TM) fractional flow reserve (FFR) technology impacts patient outcomes in Acute Coronary Syndrome (ACS) and a comparison of left atrial appendage occlusion (LAAO) therapy to standard medical treatment - were presented during hotline sessions.
STJ: 77.52 (+0.17)
St. Jude Medical Announces European Launch of the Latest in PressureWire Guidewire Technology to Measure Pressure Differences Across Narrowed Coronary Arteries
BusinessWire - Wed May 18, 7:00AM CDT
St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced CE Mark approval and European launch of the PressureWire(TM) X Guidewire fractional flow reserve (FFR) Measurement System. Designed to identify the severity of narrowings in the coronary arteries of patients with coronary artery disease (CAD), FFR measurement allows for a more effective assessment of coronary lesions (blockages), resulting in more accurate diagnosis. The company will showcase the new PressureWire X guidewire technology at the EuroPCR 2016 meeting, May 17-20, 2016 in Paris. The PressureWire X guidewire European launch will include a measured rollout to targeted countries throughout 2016.
STJ: 77.52 (+0.17)
BRIC Prosthetic Heart Valves Market Outlook to 2021 - Key Players are Edwards Lifesciences, Medtronic & St. Jude Medical, Inc - Research and Markets
BusinessWire - Tue May 17, 4:16AM CDT
Research and Markets has announced the addition of the "BRIC Prosthetic Heart Valves Market Outlook to 2021" report to their offering.
STJ: 77.52 (+0.17)
Asia-Pacific Prosthetic Heart Valves Market Outlook to 2021 - Key Players are Edwards Lifesciences Corporation, Medtronic plc, St. Jude Medical - Research and Markets
BusinessWire - Mon May 16, 8:00AM CDT
Research and Markets has announced the addition of the "Asia-Pacific Prosthetic Heart Valves Market Outlook to 2021" report to their offering.
MDT: 86.15 (+0.45), STJ: 77.52 (+0.17)
France Cardiovascular Devices Market Outlook to 2021 Featuring Key Players, Medtronic, Boston Scientific, St. Jude Medical, Inc & Abbott Laboratories - Research and Markets
BusinessWire - Mon May 16, 7:49AM CDT
Research and Markets has announced the addition of the "France Cardiovascular Devices Market Outlook to 2021" report to their offering.
BSX: 23.04 (+0.02), ABT: 38.36 (-0.04), MDT: 86.15 (+0.45), STJ: 77.52 (+0.17)
St. Jude Medical Furthers the Company's Legacy of Heart Valve Excellence With US Launch of the Trifecta Surgical Valve With Glide Technology
BusinessWire - Mon May 16, 7:00AM CDT
St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced the U.S. launch of the company's most advanced tissue valve -- the Trifecta(TM) valve with Glide(TM) Technology (GT) -- for the treatment of patients diagnosed with unhealthy, damaged or malfunctioning aortic heart valves. Designed with feedback from a cohort of international physicians, the Trifecta GT tissue valve offers patients the benefit of enhanced valve delivery to ease implantation in challenging anatomies and during minimally invasive surgical approaches.
STJ: 77.52 (+0.17)
St. Jude Medical (STJ) Shares March Higher, Can It Continue?
Zacks Equity Research - Zacks Investment Research - Thu May 12, 8:52AM CDT
As of late, it has definitely been a great time to be an investor in St. Jude Medical Inc. (STJ)
STJ: 77.52 (+0.17)
Downgrade Alert for St Jude Medical (STJ)
Comtex SmarTrend(R) - Thu May 12, 3:08AM CDT
St Jude Medical (NYSE:STJ) was downgraded from Overweight to Equal Weight at Barclays Capital today. The stock closed yesterday at $75.68 on volume of 4.6 million shares, above average daily volume of 4.3 million. Based on a current price of $75.68, St Jude Medical is currently 2.4% above its average consensus analyst price target of $73.85. The stock should discover initial support at its 200-day moving average (MA) of $62.17 and subsequent support at its 50-day MA of $58.64.
STJ: 77.52 (+0.17)
EU5 Cardiovascular Prosthetic Devices Market Report 2016-2021 - Analysis, Technologies & Forecasts - Key Vendors: Medtronic, St. Jude Medical, Sorin - Research and Markets
BusinessWire - Tue May 10, 11:14AM CDT
Research and Markets has announced the addition of the "EU5 Cardiovascular Prosthetic Devices Market Outlook to 2021" report to their offering.
MDT: 86.15 (+0.45), STJ: 77.52 (+0.17)
